NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,677−0.09%VIX25.64−9.01%latest tape · as of 20:08 UTC
The Screen · Healthcare · Biotechnology
DRUGBright Minds Biosciences Inc.
DRUG · Nasdaq · USD · Market cap $583M · 26 employees
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
FAIL · Does not pass the screen
54.98 USD
Price as of 30 Oct 2026Daily close, not a live quoteLast reviewed 8 days ago
Screened 2026-10-30 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price54.98 USD at the 30 Oct 2026 close
Fair valueUnder review: our model's value is 2.62x the price, above our 2.00x limit.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-10-29
Ethical does not pass the values gate
Price54.98 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-06Read Distribution54.98+0.0% to today Accumulation gives way to Distribution
2026-10-30Read Accumulation56.69-3.0% to today Markdown gives way to Accumulation
2026-10-02Read Markdown59.46-7.5% to today ✓Accumulation gives way to Markdown first Markdown read since July
2026-08-27Read Accumulation60.95-9.8% to today Markdown gives way to Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Bright Minds Biosciences Inc. holds its Distribution at $54.98. The statistical read favours the sellers, held for 460 days.
As held on the ledger · 2026-10-30
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 460 days
Price at the screen
$54.98
Valuation
N/A trailing · -7.05 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-0.11
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.15%
Below 33%
Interest-bearing debt is just 0.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
98.70%
Below 49%
Money owed to the company is 98.7% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Bright Minds Biosciences's business is fine, but its receivables are about 99% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DRUG's ethical verdict changes
Today DRUG does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.62x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DRUG trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 119%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it strong buy, with a mean price target of $169.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 119%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it strong buy, with a mean price target of $169.
2026-10-23Markdown$51.36+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 119%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it strong buy, with a mean price target of $169.
2026-10-16Markdown$51.36-13.6%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 13.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 119%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it strong buy, with a mean price target of $169.
2026-10-02Markdown · changed$59.46-2.4%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 119%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it strong buy, with a mean price target of $169.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 119%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it strong buy, with a mean price target of $169.
2026-07-26Markdown$60.95+0.0%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 119%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it strong buy, with a mean price target of $169.
2026-07-18Markdown$60.95+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 119%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it strong buy, with a mean price target of $169.
2026-07-03Markdown$60.95+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$60.95Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$86.55
-28.4%
·
$716
-28.4%
2 months
$83.55
-25.9%
·
$742
-25.9%
3 months
$72.25
-14.3%
·
$857
-14.3%
6 months
$89.01
-30.4%
·
$696
-30.4%
1 year
$28.27
+119.1%
·
$2,191
+119.1%
2 years
$1.11
+5,506.3%
·
$56,063
+5,506.3%
3 years
$2.76
+2,148.6%
·
$22,486
+2,148.6%
5 years
$22.35
+177.2%
·
$2,772
+177.2%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever DRUG does next, these words stay.
Bright Minds Biosciences Inc. · DRUG · Distribution · $54.98
Recorded 2026-10-30 · before the outcome · scored mechanically